2.16
price up icon24.14%   0.42
after-market 시간 외 거래: 2.11 -0.05 -2.31%
loading
전일 마감가:
$1.74
열려 있는:
$1.81
하루 거래량:
9.34M
Relative Volume:
1.08
시가총액:
$449.76M
수익:
$176.23M
순이익/손실:
$-257.83M
주가수익비율:
-1.4897
EPS:
-1.45
순현금흐름:
$-246.00M
1주 성능:
+8.00%
1개월 성능:
+176.57%
6개월 성능:
+288.63%
1년 성능:
+369.57%
1일 변동 폭
Value
$1.72
$2.175
1주일 범위
Value
$1.68
$2.175
52주 변동 폭
Value
$0.2911
$2.30

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
명칭
Sangamo Therapeutics Inc
Name
전화
(510) 970-6000
Name
주소
501 CANAL BLVD., RICHMOND, CA
Name
직원
405
Name
트위터
@sangamotx
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
SGMO's Discussions on Twitter

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-04-28 다운그레이드 BofA Securities Neutral → Underperform
2023-02-27 업그레이드 Wedbush Neutral → Outperform
2023-01-06 다운그레이드 BofA Securities Buy → Neutral
2022-06-13 재개 Wedbush Neutral
2021-05-04 개시 RBC Capital Mkts Outperform
2021-01-07 재개 Guggenheim Neutral
2021-01-06 개시 Stifel Hold
2020-12-16 재개 H.C. Wainwright Buy
2020-09-08 개시 BofA Securities Buy
2020-07-07 개시 SunTrust Buy
2019-08-26 개시 H.C. Wainwright Buy
2018-11-14 다운그레이드 JP Morgan Overweight → Neutral
2018-11-09 다운그레이드 Guggenheim Buy → Neutral
2018-10-10 개시 Guggenheim Buy
2018-06-20 개시 BofA/Merrill Buy
2017-11-15 업그레이드 Piper Jaffray Neutral → Overweight
2017-06-22 재개 Jefferies Buy
2016-11-01 다운그레이드 Wedbush Outperform → Neutral
2016-10-19 다운그레이드 Piper Jaffray Overweight → Neutral
2015-12-04 개시 Wells Fargo Outperform
2015-10-23 재개 Jefferies Buy
2013-05-03 개시 BioLogic Equity Research Sell
2011-02-23 재확인 JMP Securities Mkt Outperform
2010-07-29 재확인 Wedbush Outperform
2009-10-19 개시 Brean Murray Sell
2009-10-07 재확인 Leerink Swann Outperform
2009-08-25 재확인 JMP Securities Mkt Outperform
모두보기

Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스

pulisher
03:59 AM

Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

03:59 AM
pulisher
10:07 AM

HC Wainwright Forecasts Strong Price Appreciation for Sangamo Therapeutics (NASDAQ:SGMO) Stock - MarketBeat

10:07 AM
pulisher
03:51 AM

Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com

03:51 AM
pulisher
Nov 04, 2024

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan

Nov 04, 2024
pulisher
Nov 01, 2024

individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World

Nov 01, 2024
pulisher
Nov 01, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat

Nov 01, 2024
pulisher
Oct 26, 2024

StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News

Oct 26, 2024
pulisher
Oct 25, 2024

Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News

Oct 25, 2024
pulisher
Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 23, 2024

4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga

Oct 23, 2024
pulisher
Oct 23, 2024

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter

Oct 23, 2024
pulisher
Oct 22, 2024

Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug - MarketWatch

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo stock rallies 37% on FDA update for Fabry disease drug (NASDAQ:SGMO) - Seeking Alpha

Oct 22, 2024
pulisher
Oct 22, 2024

CBER’s lean into accelerated approval slashes three years from Sangamo gene therapy - BioCentury

Oct 22, 2024
pulisher
Oct 22, 2024

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire

Oct 22, 2024
pulisher
Oct 21, 2024

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec… Trifecta Soon? (NASDAQ:SGMO) - Seeking Alpha

Oct 21, 2024
pulisher
Oct 17, 2024

Cubist Systematic Strategies LLC Purchases Shares of 185,813 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

Oct 17, 2024
pulisher
Oct 15, 2024

Are Smart Investors Making the Right Decision? Sangamo Therapeutics Inc (SGMO) - SETE News

Oct 15, 2024
pulisher
Oct 15, 2024

Sangamo Therapeutics Inc Inc. (SGMO) Price Performance: The Role of Supply and Demand - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

Observations on the Sangamo Therapeutics Inc (NASDAQ:SGMO) Growth Curve - US Post News

Oct 14, 2024
pulisher
Oct 11, 2024

Sangamo Therapeutics Inc (SGMO) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Oct 11, 2024
pulisher
Oct 09, 2024

Sangamo Therapeutics Inc [SGMO] Investment Guide: What You Need to Know - Knox Daily

Oct 09, 2024
pulisher
Oct 08, 2024

The growth track for Sangamo Therapeutics Inc (SGMO) has changed recently - SETE News

Oct 08, 2024
pulisher
Oct 08, 2024

Genome Editing Market Analysis 2031, Competitive Landscape, Factors, Factors And Competition | Horizon Discovery Group, Lonza, Merck KGaA, Sangamo Therapeutics, Thermo Fisher Scientific – Times-BD24 - Times-BD24

Oct 08, 2024
pulisher
Oct 07, 2024

A closer look at Sangamo Therapeutics Inc’s (SGMO) current quarter earnings projections - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Balance Sheet Breakdown: Sangamo Therapeutics Inc (SGMO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Oct 07, 2024
pulisher
Oct 05, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Acquired by Renaissance Technologies LLC - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Sangamo seeks court validation for stock amendment - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Sangamo seeks court validation for stock amendment By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Oct 04, 2024

Sangamo Therapeutics Seeks Court Approval for Stock Amendment - TipRanks

Oct 04, 2024
pulisher
Oct 02, 2024

Investing in Sangamo Therapeutics Inc (SGMO) Is Getting More Attractive - Knox Daily

Oct 02, 2024
pulisher
Oct 01, 2024

5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io

Oct 01, 2024
pulisher
Sep 30, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Point72 Asia Singapore Pte. Ltd. Makes New $89,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

Sep 30, 2024
pulisher
Sep 27, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Cross Above 200-Day Moving Average of $0.64 - MarketBeat

Sep 27, 2024
pulisher
Sep 27, 2024

Armistice Capital LLC Sells 2,898,477 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Sep 27, 2024
pulisher
Sep 27, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Passes Above 200-Day Moving Average of $0.64 - Defense World

Sep 27, 2024
pulisher
Sep 26, 2024

Haemophilia Gene Therapy Market Recent Developments & Growth Opportunities 2022-2030 | BioMarin Pharmaceuticals Inc., F Hoffmann-La Roche AG, Freeline Therapeutics, Pfizer, Sangamo Therapeutics Inc. – Cauverynews - Cauverynews

Sep 26, 2024
pulisher
Sep 23, 2024

A Tale of Resilience: Sangamo Therapeutics Inc Amid Stock Market Turbulence - The InvestChronicle

Sep 23, 2024
pulisher
Sep 21, 2024

Retail investors who hold 56% of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) gained 13%, institutions profited as well - Simply Wall St

Sep 21, 2024
pulisher
Sep 21, 2024

Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week - Yahoo Finance

Sep 21, 2024
pulisher
Sep 19, 2024

Sangamo Therapeutics Target of Unusually High Options Trading (NASDAQ:SGMO) - MarketBeat

Sep 19, 2024
pulisher
Sep 16, 2024

Press Release Service: Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex PharmaceuticalsResearchAndMarkets.comC - CRISPR Medicine News

Sep 16, 2024

Sangamo Therapeutics Inc (SGMO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):